DoubleIdat.i
Curation
Accueil
Racine
Curation
Exploration
Accueil
Racine
Accueil
Racine

Serveur d'exploration Tocilizumab - Curation (Accueil)

Index « DoubleIdat.i » - tête de navigation
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Index : DoubleIdat.i

Pour accéder à une entrée :

Les termes de plus forte occurence

11615-9306:2008:Taga A:analysis:of:an
11567-5769:2008:Uchiyama Y:anti:il:receptor
11567-5769:2005:Mihara M:tocilizumab:inhibits:signal
11462-0324:2010:Shima Y:the:skin:of
11462-0324:2008:Hashizume M:il:trans:signalling
11368-5031:2011:Alves J:tocilizumab:is:there
11080-0549:2005:Yokota S:clinical:study:of
11080-0549:2005:Smolen J:pro:inflammatory:cytokines
11080-0549:2005:Nishimoto N:clinical:studies:in
11078-0432:2011:Tawara I:interleukin:modulates:graft
11053-8569:2013:Curtis J:identifying:newly:approved
10946-1965:2013:Zhang X:pharmacokinetics:and:pharmacodynamics
10946-1965:2013:Xiaoping Zhang:pharmacokinetics:and:pharmacodynamics
10946-1965:2013:Morcos P:pharmacokinetics:and:pharmacodynamics
10925-5710:2007:Kanda J:reversible:cardiomyopathy:associated
10379-0355::Bayes M:gateways:to:clinical
10379-0355:2010:Tomillero A:gateways:to:clinical
10379-0355:2009:Tomillero A:gateways:to:clinical
10379-0355:2008:Tomillero A:gateways:to:clinical
10379-0355:2007:Bayes M:gateways:to:clinical
10379-0355:2005:Bayes M:gateways:to:clinical
10340-1855:2011:Kruger K:kombinationsbehandlung:von:methotrexat
10340-1855:2010:Wollenhaupt J:nicht:tnf:biologika
10340-1855:2010:Gause A:empfehlungen:der:deutschen
10315-162X:2014:Yokota S:longterm:safety:and
10315-162X:2014:Koike T:effectiveness:and:safety
10315-162X:2014:Keystone E:continued:benefit:of
10315-162X:2014:Elkayam O:tocilizumab:in:adult
10315-162X:2014:Aoki C:discrepancy:between:clinical
10315-162X:2013:Tombetti E:treatment:of:refractory
10315-162X:2013:Shimamoto K:serum:interleukin:before
10315-162X:2013:Ikeda K:correlation:of:radiographic
10315-162X:2013:Genovese M:longterm:safety:and
10315-162X:2013:Fleischmann R:tocilizumab:inhibits:structural
10315-162X:2013:Aguilar Lozano L:sustained:clinical:remission
10315-162X:2012:Richez C:tocilizumab:treatment:decreases
10315-162X:2012:Mesko B:peripheral:blood:gene
10315-162X:2012:Fragiadaki K:sleep:disturbances:and
10315-162X:2011:Singh J:tocilizumab:for:rheumatoid
10315-162X:2011:Roux C:ophthalmic:herpes:zoster
10315-162X:2011:Launois R:comparison:of:certolizumab
10315-162X:2011:Kume K:tocilizumab:monotherapy:reduces
10315-162X:2009:Kawashiri S:proinflammatory:cytokines:synergistically
10303-464X::Fonseca J:portuguese:guidelines:for
10301-1526:2012:Schumacher A:castleman:s:disease
10277-0008:2011:Devine E:effectiveness:of:biologic
10269-4727:2013:Carnovale C:a:case:of
10171-2004:2008:Nishimoto N:humanized:antihuman:il
10040-5957:2011:Fabre S:approches:pharmacologiques:en
10032-5473:2010:Suresh E:recent:advances:in
10022-3417:2011:Shinriki S:interleukin:signalling:regulates
10022-3085:2009:Kudo M:antitumor:effect:of
10021-9746:2010:Sato Y:multicentric:castleman:s
10012-6667:2009:Oldfield V:tocilizumab:a:review
10008-5472:2007:Yoshio Hoshino N:establishment:of:a
10007-0963:2014:Jayasekera P:a:case:of
10007-0963:2010:Laurent S:onset:of:psoriasis
10004-3591:2010:Illei G:tocilizumab:in:systemic
10004-3591:2010:Garnero P:rapid:and:sustained
10004-3591:2008:Nishimoto N:successful:treatment:of
10004-3591:2008:Genovese M:interleukin:receptor:inhibition
10004-3591:2006:Okuda Y:successful:use:of
10004-3591:2006:Maini R:double:blind:randomized
10003-4967:2013:Specker C:ab:tocilizumab:in
10003-4967:2013:Shirota Y:impact:of:anti
10003-4967:2013:Kume K:ab:tocilizumab:improves
10003-4967:2013:Kanayama Y:ab:radiographic:progression
10003-4967:2013:Foeldvari I:ab:looking:for
10003-4967:2013:Dougados M:adding:tocilizumab:or
10003-4967:2012:Yazici Y:efficacy:of:tocilizumab
10003-4967:2012:Smolen J:tocilizumab:inhibits:progression
10003-4967:2012:Schoels M:comparative:effectiveness:and
10003-4967:2012:Sakai R:drug:retention:rates
10003-4967:2012:Mori S:impact:of:tocilizumab
10003-4967:2012:Cohen C:efficacy:of:tocilizumab
10003-4967:2012:Bykerk V:tocilizumab:in:patients
10003-4967:2011:Salliot C:indirect:comparisons:of
10003-4967:2011:Ogata A:improvement:of:hba
10003-4967:2011:Muhammad K:impact:of:il
10003-4967:2011:Leffers H:efficacy:of:abatacept
10003-4967:2011:Koike T:postmarketing:surveillance:of
10003-4967:2011:Inaba Y:radiographic:improvement:of
10003-4967:2011:Iking Konert C:performance:of:the
10003-4967:2011:Burmester G:effectiveness:and:safety
10003-4967:2010:Nam J:current:evidence:for
10003-4967:2010:Jones G:comparison:of:tocilizumab
10003-4967:2010:Henes J:mixed:response:to
10003-4967:2009:Nishimoto N:long:term:safety
10003-4967:2009:Hirao M:laboratory:and:febrile
10003-4967:2009:De Bandt M:tocilizumab:for:multirefractory
10003-4967:2008:Emery P:il:receptor:inhibition
10003-4967:2007:Sacre S:could:toll:like
10003-4967:2007:Nishimoto N:study:of:active

Manipulations en shell (Unix/Dilib)

HfdCat /Users/jacquesducloy/Documents/WicriRoot/Wicri/Sante/explor/Tocilizumab.storage/TocilizumabV1/Data/Main/Curation/DoubleIdat.i.hfd| SxmlCut idx/l | grep ...
Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021